Recursion Pharmaceuticals, Inc. (RXRX)
3.32
-0.08
(-2.35%)
USD |
NASDAQ |
Sep 01, 16:00
3.34
+0.02
(+0.60%)
After-Hours: 20:00
Recursion Pharmaceuticals Total Long Term Debt (Quarterly) : 53.39M for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 53.39M |
| March 31, 2026 | 59.29M |
| December 31, 2025 | 65.30M |
| September 30, 2025 | 70.85M |
| June 30, 2025 | 76.34M |
| March 31, 2025 | 81.06M |
| December 31, 2024 | 94.70M |
| September 30, 2024 | 82.39M |
| June 30, 2024 | 81.27M |
| March 31, 2024 | 44.91M |
| December 31, 2023 | 44.56M |
| September 30, 2023 | 46.12M |
| June 30, 2023 | 47.68M |
| Date | Value |
|---|---|
| March 31, 2023 | 48.61M |
| December 31, 2022 | 45.05M |
| September 30, 2022 | 46.65M |
| June 30, 2022 | 48.44M |
| March 31, 2022 | 48.02M |
| December 31, 2021 | 11.48M |
| September 30, 2021 | 5.62M |
| June 30, 2021 | 15.48M |
| March 31, 2021 | 15.54M |
| December 31, 2020 | 15.66M |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| Twist Bioscience Corp. | 84.96M |
| Absci Corp. | 1.792M |
| Novavax, Inc. | 297.32M |
| Editas Medicine, Inc. | 64.74M |
| Halozyme Therapeutics, Inc. | 2.147B |